Does RANIBIZUMAB Cause Malignant neoplasm progression? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Malignant neoplasm progression have been filed in association with RANIBIZUMAB (CIMERLI). This represents 0.1% of all adverse event reports for RANIBIZUMAB.
9
Reports of Malignant neoplasm progression with RANIBIZUMAB
0.1%
of all RANIBIZUMAB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RANIBIZUMAB?
Of the 9 reports, 2 (22.2%) resulted in death, 3 (33.3%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RANIBIZUMAB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does RANIBIZUMAB Cause?
Death (2,250)
Off label use (1,467)
Visual acuity reduced (1,342)
Visual impairment (1,185)
No adverse event (1,012)
Drug ineffective (831)
Blindness (760)
Vision blurred (711)
Eye pain (632)
Cerebrovascular accident (543)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RANIBIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
RANIBIZUMAB vs RANIMUSTINE
RANIBIZUMAB vs RANITIDINE
RANIBIZUMAB vs RANITIDINE\RANITIDINE
RANIBIZUMAB vs RANOLAZINE
RANIBIZUMAB vs RAPAMUNE